Sina Naserian
French Institute of Health and Medical Research
Cell therapyTumor necrosis factor alphaMesenchymal stem cellProgenitor cellIn vitroImmunologyT cellInflammationHematopoietic stem cell transplantationFOXP3Context (language use)AngiogenesisImmune checkpointStem cellTransplantationCancer researchMedicineIL-2 receptorBiologyImmune systemCell biology
30Publications
10H-index
388Citations
Publications 25
Newest
#1Sina Naserian (French Institute of Health and Medical Research)H-Index: 10
#2Georges Uzan (French Institute of Health and Medical Research)H-Index: 35
Source
#1Mohammad Mirzakhani (Babol University of Medical Sciences)H-Index: 5
#2Mehdi Shahbazi (Babol University of Medical Sciences)H-Index: 9
Last. Mousa Mohammadnia-Afrouzi (Babol University of Medical Sciences)H-Index: 14
view all 5 authors...
The immune system response of transplant recipients is the main cause of allograft rejection; therefore, its suppression seems crucial. Nevertheless, immunosuppressive agents are largely ineffective against innate immune response. Innate immunity is immediately activated after transplantation and contribute to allograft inflammation and rejection. In this regard, understanding the mechanism of activation and targeting the components of innate immunity could improve allograft survival time. In th...
1 CitationsSource
#1Mahsa Nouri Barkestani (French Institute of Health and Medical Research)H-Index: 2
#2Sina Naserian (French Institute of Health and Medical Research)H-Index: 10
Last. Sara Shamdani (French Institute of Health and Medical Research)H-Index: 3
view all 4 authors...
Due to the current lack of innovative and effective therapeutic approaches, tissue engineering (TE) has attracted much attention during the last decades providing new hopes for the treatment of sev...
Source
#2Sara ShamdaniH-Index: 3
Last. Sina NaserianH-Index: 10
view all 7 authors...
Source
#1Mohamed Essameldin Abdelgawad (Helwan University)H-Index: 7
#2Christophe DesterkeH-Index: 11
Last. Sina Naserian (French Institute of Health and Medical Research)H-Index: 10
view all 4 authors...
BACKGROUND Endothelial progenitor cells (EPCs) are promising candidates for the cellular therapy of peripheral arterial and cardiovascular diseases. However, hitherto there is no specific marker(s) defining precisely EPCs. Herein, we are proposing a new in silico approach for finding novel EPC markers. METHODS We assembled five groups of chosen EPC-related genes/factors using PubMed literature and Gene Ontology databases. This shortened database of EPC factors was fed into publically published t...
Source
#1Sina Naserian (French Institute of Health and Medical Research)H-Index: 10
#2Mathieu Leclerc (French Institute of Health and Medical Research)H-Index: 6
Last. Georges Uzan (French Institute of Health and Medical Research)H-Index: 35
view all 4 authors...
Graft versus host disease (GVHD) is one of the main causes of mortality and the reason for up to 50 % of morbidity after hematopoietic stem cell transplantations (HSCT) which is the treatment of choice for many blood malignancies. Thanks to years of research and exploration, we have acquired a profound understanding of the pathophysiology and immunopathology of these disorders. This led to the proposition and development of many therapeutic approaches during the last decades, some of them with v...
1 CitationsSource
#1Sina Naserian (French Institute of Health and Medical Research)H-Index: 10
#2Sara Shamdani (French Institute of Health and Medical Research)H-Index: 3
Last. Georges Uzan (French Institute of Health and Medical Research)H-Index: 35
view all 4 authors...
Mesenchymal stem/stromal cells can modulate the effector immune cells especially T lymphocytes. Due to this important feature, they can regulate the development of a variety of disorders including inflammatory and autoimmune disorders, cancers, and transplantation outcomes. One of the most important MSC immunoregulatory functions is their capacity to convert conventional T cells into regulatory T cells. Several mechanisms, mostly related to MSCs but not T cells, have been shown essential for thi...
1 CitationsSource
#1Ghada Beldi (French Institute of Health and Medical Research)H-Index: 2
#2Sheyda Bahiraii (University of Vienna)H-Index: 1
Last. Sina Naserian (French Institute of Health and Medical Research)H-Index: 10
view all 7 authors...
Mesenchymal stem cells (MSCs) have drawn lots of attention as gold standard stem cells in fundamental and clinical researches during the last 20 years. Due to their tissue and vascular repair capacities, MSCs have been used to treat a variety of degenerative disorders. Moreover, MSCs are able to modulate immune cells' functions, particularly T cells while inducing regulatory T cells (iTregs). MSCs are very sensitive to inflammatory signals. Their biological functions could remarkably vary after ...
6 CitationsSource
#1Yu Y (Peking Union Medical College)H-Index: 1
#2Valderrama Av (French Institute of Health and Medical Research)H-Index: 1
Last. Estelle Oberlin (French Institute of Health and Medical Research)H-Index: 7
view all 6 authors...
Mesenchymal stem cells (MSCs) exhibit active abilities to suppress or modulate deleterious immune responses by various molecular mechanisms. These cells are the subject of major translational efforts as cellular therapies for immune-related diseases and transplantations. Plenty of preclinical studies and clinical trials employing MSCs have shown promising safety and efficacy outcomes and also shed light on the modifications in the frequency and function of regulatory T cells (T regs). Neverthele...
1 CitationsSource
#1Mahsa Nouri Barkestani (French Institute of Health and Medical Research)H-Index: 2
#2Sara Shamdani (French Institute of Health and Medical Research)H-Index: 3
Last. Sina Naserian (French Institute of Health and Medical Research)H-Index: 10
view all 7 authors...
BACKGROUND Bone marrow derived endothelial progenitor cells (EPCs) are immature endothelial cells (ECs) involved in neo-angiogenesis and endothelial homeostasis and are considered as a circulating reservoir for endothelial repair. Many studies showed that EPCs from patients with cardiovascular pathologies are impaired and insufficient; hence, allogenic sources of EPCs from adult or cord blood are considered as good choices for cell therapy applications. However, allogenic condition increases the...
3 CitationsSource